NYSE:TMOLife Sciences
Thermo Fisher Scientific (NYSE:TMO) Gains FDA Approval for Rapid Cancer Diagnostic Tool
Thermo Fisher Scientific (NYSE:TMO) recently achieved a 7% price increase following the FDA approval of its Oncomine™ Dx Express Test. This approval, enabling rapid genomic testing, bolsters the company's position in precision oncology and positively impacts investor sentiment. The FDA's decision in early July underscored Thermo Fisher's commitment to advancing diagnostic solutions, which aligns with industry trends toward expedited drug development. Additionally, its strategic collaborations...